PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics announces that four abstracts on the ChemoFx® in vitro drug response marker have been accepted for poster presentation at the International Gynecologic Cancer Society (IGCS) Annual Meeting, which will be held in Vancouver October 13-16, 2012.
The first abstract, submitted by Dr. Charles A. Leath III and titled, Evaluation of a Prospective Observational Trial Utilizing The ChemoFx® Chemosensitivity and Resistance Assay (CSRA) In Epithelial Ovarian Cancer, demonstrates physician practice patterns as well as the clinical utility of ChemoFx for patients with epithelial ovarian cancer.
An abstract submitted by Dr. Perry W. Grigsby and titled, In Vitro Chemoresponse Analysis and Clinical Outcomes in Cervical Cancer, reports the association between ChemoFx test results and recurrence-free survival (RFS) of cervical cancer patients. This analysis further supports the use of ChemoFx for helping with treatment decisions for cervical cancer patients.
Dr. Dennis Scribner authored the third abstract, titled, Does In-Vitro Chemosensitivity Show Synergy When Comparing Single Agents to Platinum-Based Combinations in Ovarian Cancer. This data shows ChemoFx patterns of response to commonly administered treatments, and analyzes trends between single agents versus doublet therapies.
The final abstract, In Vitro Chemoresponse Assessment of Optimally and Sub-Optimally Debulked Primary Ovarian Cancer), submitted by Dr. Jill Whyte, compares ChemoFx results in optimally and sub-optimally debulked primary ovarian cancer patient specimens to begin understanding differences in tumor biology within these patient sets.
“Gynecologic cancers, specifically recurrent gynecologic cancers, can be extremely difficult to treat,” says Dr. Karl Williams, Chief Medical Director for Precision Therapeutics, Inc. “This promising data further examines the utility of ChemoFx results in refining and personalizing treatment for these poor prognosis patients.”
About Precision Therapeutics
Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.
Precision's state of the art Comprehensive Tumor Profiling is an integrated, straightforward approach combining three core platforms of personalized medicine to capture the total sum of genomic, proteomic and functional information for each patient's cancer.
Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. Precision currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. To date, approximately 80,000 patient specimens have been submitted for ChemoFx® testing using 105 unique chemotherapy treatments and combinations.